Group 1 - The company expects a net profit of 100 million to 130 million yuan for the current reporting period, a decrease of 39.95% to 53.81% compared to the same period last year, where the net profit was 216.48 million yuan [1] - The expected net profit after deducting non-recurring gains and losses is estimated to be between 91 million and 121 million yuan, reflecting a decline of 40.50% to 55.25% from the previous year's 203.37 million yuan [1] - The primary reason for the decline in performance is attributed to significant price reductions in the company's main products due to the nationwide implementation of centralized procurement, leading to decreased revenue and profit margins [1] Group 2 - The impact of non-recurring gains and losses on net profit is estimated to be around 9 million yuan, mainly from government subsidies received [1]

Core Viewpoint - The company Fu'an Pharmaceutical (300194) expects a significant decline in net profit for the first half of 2025, primarily due to price reductions in its main products as a result of nationwide centralized procurement [1] Financial Performance - The projected net profit attributable to shareholders for the period from January 1, 2025, to June 30, 2025, is estimated to be between 100 million to 130 million yuan, representing a year-on-year decrease of 39.95% to 53.81% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 91 million to 121 million yuan, reflecting a year-on-year decline of 40.50% to 55.25% [1] Market Conditions - The decline in performance is primarily attributed to the implementation of centralized procurement across the country, which has led to a substantial decrease in the sales prices of the company's main products [1]

[Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company forecasts a year-over-year decline in its 2025 first-half performance, with net profit attributable to shareholders expected to decrease by 39.95% to 53.81% Performance Forecast Table | Item | Current Period (2025H1) Forecast | Prior Period | Year-over-Year Change | | :--- | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | Profit: 100 million CNY – 130 million CNY | Profit: 216.4775 million CNY | Decrease: 39.95% - 53.81% | | **Net Profit Excluding Non-Recurring Gains and Losses** | Profit: 91 million CNY – 121 million CNY | Profit: 203.3734 million CNY | Decrease: 40.50% - 55.25% | [Explanation of Performance Change](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The company's performance decline is primarily due to the nationwide implementation of centralized drug procurement policies, which significantly reduced product prices and compressed profit margins - The core reason for the performance decline is the **significant reduction in sales prices** of the company's main products due to the nationwide implementation of centralized drug procurement (NCDP), leading to **lower operating revenue** and **compressed profit margins**[5](index=5&type=chunk)[6](index=6&type=chunk) - Non-recurring gains and losses are estimated to have a positive impact of approximately **9 million CNY** on net profit during the current reporting period, primarily from government subsidies[6](index=6&type=chunk) [Other Explanations and Risk Warnings](index=1&type=section&id=%E5%9B%9B%E3%80%81%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) The company emphasizes that the financial data in this performance forecast are preliminary, unaudited estimates, with final figures to be disclosed in the 2025 semi-annual report, urging investors to be aware of investment risks - The financial data in this performance forecast are **preliminary estimates** and **unaudited** by a certified public accountant, thus subject to uncertainty[4](index=4&type=chunk)[7](index=7&type=chunk) - The company advises investors that the specific and accurate financial data will be disclosed in the 2025 semi-annual report, urging caution regarding investment risks[7](index=7&type=chunk)

Group 1: Company Announcements - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and international brand image [1] - Saisir reported June sales of 46,086 new energy vehicles, a year-on-year increase of 4.44%, with a total of 172,100 units sold in the first half of the year, down 14.35% year-on-year [1] - Hangzhou High-tech announced a change in controlling shareholder to Jirong Weiye, with stock resuming trading on July 2, 2025 [1] Group 2: Financial Performance - Guomai Technology expects a net profit of 125 million to 156 million yuan for the first half of 2025, a year-on-year increase of 60.52% to 100.33% [2] - Kid King anticipates a net profit of 120 million to 160 million yuan for the first half of 2025, representing a year-on-year growth of 50% to 100% [2] - Mould Technology received a project from a well-known North American electric vehicle company, with expected total sales of 1.236 billion yuan over five years [3] Group 3: Regulatory and Compliance - *ST Yuancheng is under investigation by the China Securities Regulatory Commission for suspected false disclosures in financial reports [4] - The company received a notice of investigation on July 1, 2025, which may lead to significant penalties and potential delisting [4] Group 4: Market Activity - Changcheng Military Industry's stock has experienced significant volatility, with a cumulative price deviation exceeding 20% over three trading days, indicating potential irrational speculation [5] - Anglikang has only one innovative drug project, ALK-N001, currently in Phase I clinical trials, highlighting the long and uncertain nature of drug development [6] Group 5: Sales and Contracts - Beiqi Blue Valley's subsidiary reported a 139.73% year-on-year increase in sales for the first half of the year [7] - Dong'an Power's engine sales in June increased by 82.79% year-on-year [7] - Pudong Construction's subsidiary won multiple major projects with a total bid amount of 1.964 billion yuan [7]

Core Viewpoint - Fu'an Pharmaceutical's subsidiary Tianheng Pharmaceutical has received a drug registration certificate from the National Medical Products Administration for Adenosylcobalamin Capsules, enhancing its product line and market competitiveness [1] Company Summary - The drug is classified as a Class 3 chemical drug with a specification of 0.5mg [1] - The drug is indicated for the treatment of megaloblastic anemia and has passed consistency evaluations by several other companies [1] - The approval number for the drug is Guoyao Zhunzi H20254594, and Tianheng Pharmaceutical is the marketing authorization holder [1] Industry Summary - The registration of this drug will enrich the product portfolio of the subsidiary, potentially increasing its competitive edge in the pharmaceutical market [1]

证券代码：300194 证券简称：福安药业 公告编号：2025-021 上述药品注册证书的获得将进一步丰富子公司产品线，提升其市场竞争力。 但上述产品受国家政策、市场环境变化等因素影响，产品的生产、销售情况以及 对公司业绩的具体影响存在不确定性。请广大投资者审慎决策，注意投资风险。 特此公告 福安药业（集团）股份有限公司 董事会 二〇二五年七月一日 关于子公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称"公司"）全资子公司福安药业集 团宁波天衡制药有限公司（以下简称"天衡制药"）于近日收到国家药品监督管 理局签发的药品注册证书，现将具体情况公告如下： | 药品名称 | 注册分类 | 规格 | 药品上市许 可持有人 | 批准文号 | | 审批结论 | | --- | --- | --- | --- | --- | --- | --- | | 腺苷钴胺胶囊 | 化学药品 3 类 | 0.5mg | 天衡制药 | 国 药 H20254594 | 准 字 | 经审查，本品符合药品注册 的有关要求，批 ...

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 证券代码：300194 证券简称：福安药业 公告编号：2025-020 福安药业（集团）股份有限公司 关于子公司收到药品注册证书的公告 上述药品注册证书的获得将进一步丰富子公司产品线，提升其市场竞争力。 但上述产品受国家政策、市场环境变化等因素影响，产品的生产、销售情况以及 对公司业绩的具体影响存在不确定性。请广大投资者审慎决策，注意投资风险。 特此公告 福安药业（集团）股份有限公司 董事会 二〇二五年六月十日 福安药业（集团）股份有限公司（以下简称"公司"）全资子公司福安药业集 团庆余堂制药有限公司（以下简称"庆余堂"）于近日收到国家药品监督管理局 签发的药品注册证书，现将具体情况公告如下： | 药品名称 | 注册分类 | 规格 | 药品上市许 可持有人 | 批准文号 | | 审批结论 | | --- | --- | --- | --- | --- | --- | --- | | 注射用苯唑西林钠 | 化学药品 3 | 2.0g 类 | 庆余堂 | 国 药 准 H20254446 | 字 | 经审查，本品符 ...

Core Viewpoint - The company has announced its profit distribution plan for the fiscal year 2024, which includes a cash dividend of 0.50 RMB per 10 shares, totaling approximately 59.49 million RMB to be distributed to shareholders [1][2]. Summary by Sections Profit Distribution Plan - The profit distribution plan was approved at the annual shareholders' meeting held on May 15, 2025, with a total share capital of 1,189,712,382 shares as the basis for the distribution [1][2]. - The cash dividend of 0.50 RMB per 10 shares will be distributed to all shareholders, amounting to a total of 59,485,619.10 RMB (including tax) [1][2]. Implementation Details - The distribution will not include stock dividends or capital reserve transfers to increase share capital [1]. - The cash dividend will be subject to different tax rates for various categories of shareholders, with specific provisions for Hong Kong investors and domestic investors [2]. Key Dates - The record date for the distribution is set for May 27, 2025, and the ex-dividend date is May 28, 2025 [2][3]. Distribution Method - Cash dividends will be directly credited to shareholders' accounts through their custodial securities companies or other custodial institutions [3]. Contact Information - For inquiries, shareholders can contact the company's securities department located in Chongqing, with provided contact details for further assistance [3].

2024年度权益分派实施公告 证券代码：300194 证券简称：福安药业 公告编号：2025-019 福安药业（集团）股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称"公司"）2024 年年度权益分派 方案已获 2025 年 5 月 15 日召开的 2024 年年度股东大会审议通过，现将权益 分派事宜公告如下： 一、股东大会审议通过利润分配方案情况 1、2025 年 4 月 23 日，公司第六届董事会第二次会议审议通过了《关于公 司 2024 年度利润分配预案的议案》，详细情况请见公司于 2025 年 4 月 24 日在 中国证监会指定信息披露网站上披露的《关于公司 2024 年度利润分配预案的公 告》。 公司于 2025 年 5 月 15 日召开 2024 年度股东大会，审议通过了《关于公 司 2024 年度利润分配方案的议案》。公司 2024 年度利润分配方案为：以公司现 有总股本 1,189,712,382 股为基数，向全体股东每 10 股派发现金股利 0.50 元人 民币（含税），共计派发现金股利 ...

上 海 东 方 华 银 律 师 事 务 所 C A P I T A L L A W & P A R T N E RS 上海市虹桥路 1591 号虹桥迎宾馆 34 号楼 邮编：200336 电话：+86 21 68769686 Tel ：+86 21 68769686 传真：+86 21 68769686 Fax：+86 21 68769686 Building 34, Hongqiao Guesthouse, 1591 Hongqiao Rd., Shanghai，p.c: 200336 上海东方华银律师事务所 关于福安药业（集团）股份有限公司 法律意见书 致：福安药业（集团）股份有限公司 上海东方华银律师事务所（以下简称"本所"）接受福安药业（集团）股份 有限公司（以下简称"公司"或"福安药业"）委托，就公司召开 2024 年年度 股东大会（以下简称"本次股东大会"）的有关事宜，根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）等法律、法规和其他规范性文件以及《福安药业（集团）股份有 限公司章程》（以下简称"《公司章程》"）的有关规定，就公司本次 ...